NEW YORK (GenomeWeb) – Biocept announced today that cancer genomics firm Progenetics will market and distribute its complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.

Progenetics, founded in 2014 and based in Tel Aviv, Israel, provides advanced tumor profiling services. Last July, it signed an agreement with OncoDNA to provide Israeli physicians with a variety of other cancer tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.